- Title
- Baseline characteristics and ICS/LAMA/LABA response in asthma: analyses from the CAPTAIN study
- Creator
- Boulet, Louis-Philippe; Abbott, Carl; Gibson, Peter G.; Brusselle, Guy; Edwards, Dawn; Oppenheimer, John; Pavord, Ian D.; Pizzichini, Emilio; Sagara, Hironori; Slade, David; Wechsler, Michael E.
- Relation
- Journal of Allergy and Clinical Immunology: In Practice Vol. 12, Issue 5, p. 1244-1253.e8
- Publisher Link
- http://dx.doi.org/10.1016/j.jaip.2024.01.039
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2024
- Description
- Background: Findings from CAPTAIN (NCT02924688) suggest that treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) differs according to baseline type 2 inflammation markers in patients with moderate to severe asthma. Understanding how other patient physiologic and clinical characteristics affect response to inhaled therapies may guide physicians toward a personalized approach for asthma management. Objective: To investigate, using CAPTAIN data, the predictive value of key demographic and baseline physiologic variables in patients with asthma (lung function, bronchodilator reversibility, age, age at asthma onset) on response to addition of the long-acting muscarinic antagonist UMEC to inhaled corticosteroid/long-acting β2-agonist combination FF/VI, or doubling the FF dose. Methods: Prespecified and post hoc analyses of CAPTAIN data were performed using categorical and continuous variables of key baseline characteristics to understand their influence on treatment outcomes (lung function [trough FEV1], annualized rate of moderate/severe exacerbations, and asthma control [Asthma Control Questionnaire]) following addition of UMEC to FF/VI or doubling the FF dose in FF/VI or FF/UMEC/VI. Results: Adding UMEC to FF/VI led to greater improvements in trough FEV1 versus doubling the FF dose across all baseline characteristics assessed. Doubling the FF dose was generally associated with numerically greater reductions in the annualized rate of moderate/severe exacerbations compared with adding UMEC, independent of baseline characteristics. Adding UMEC and/or doubling the FF dose generally led to improvements in Asthma Control Questionnaire scores irrespective of baseline characteristics. Conclusions: Unlike previous findings with type 2 biomarkers, lung function, bronchodilator reversibility, age and age at asthma onset do not appear to predict response to inhaled therapy.
- Subject
- asthma; fluticasone furoate; umeclidinium; vilanterol; continuous analyses; categorical analyses; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1503540
- Identifier
- uon:55350
- Identifier
- ISSN:2213-2198
- Language
- eng
- Reviewed
- Hits: 2050
- Visitors: 2020
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|